AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES

被引：1
|
作者：
Winthrop, K. [1 ]
Gold, D. [2 ]
Henrohn, D. [3 ]
Wang, L. [4 ]
Shapiro, A. [5 ]
Shi, H. [6 ]
Citera, G. [7 ]
Schulze-Koops, H. [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Pfizer Inc, Montreal, PQ, Canada
[3] Pfizer Inc, Sollentuna, Sweden
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, Peapack, NJ USA
[6] Pfizer Inc, Collegeville, PA USA
[7] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina
[8] Klinikum Univ Munchen, Munich, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0139
引用
收藏
页码：1003 / 1004
页数：2
相关论文
共 32 条
  • [21] PREDICTORS OF DURABLE CLINICAL RESPONSE TO TOFACITINIB 11 MG ONCE DAILY WITH OR WITHOUT METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: POST HOC ANALYSIS OF DATA FROM A PHASE 3B/4 METHOTREXATE WITHDRAWAL STUDY
    Yamaoka, K.
    Cohen, S. B.
    Sugiyama, N.
    Shi, H.
    Rivas, J. L.
    Diehl, A.
    Smolen, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 563 - 564
  • [22] Low Patient Global Assessment Scores in Rheumatoid Arthritis Are Associated with Pain and Physical Function in Patients Treated with Tofacitinib: A Post-Hoc Analysis of Phase 3 Trials
    Strand, Vibeke
    Alten, Rieke
    Kaine, Jeffrey
    Soonasra, Arif
    Murray, Christopher W.
    Fan, Haiyun
    Mojcik, Christopher F.
    Wallenstein, Gene
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [23] Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
    Yamaoka, Kunihiro
    Cohen, Stanley B.
    Sugiyama, Naonobu
    Shi, Harry
    Rivas, Jose L.
    Diehl, Annette
    Smolen, Josef
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [24] Incidence Of Infections In Patients With Severe, Uncontrolled Asthma Treated With Tezepelumab: A Pooled Analysis Of The Phase 2b PATHWAY And Phase 3 NAVIGATOR Studies
    Menzies-Gow, Andrew
    Corren, Jonathan
    Ambrose, Chris
    Hunter, Gillian
    Fitzpatrick, Sherahe
    Hagberg, Anette
    Ponnarambil, Sandhia
    Martin, Neil
    Molfino, Nestor
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB16 - AB16
  • [25] Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
    Karpouzas, George A.
    Szekanecz, Zoltan
    Baecklund, Eva
    Mikuls, Ted
    Bhatt, Deepak L.
    Shi, Harry
    Wang, Cunshan
    Sawyerr, Gosford A.
    Chen, Yan
    Menon, Sujatha
    Connell, Carol A.
    Ytterberg, Steven R.
    Mortezavi, Mahta
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2759 - 2762
  • [26] CLINICAL AND FUNCTIONAL RESPONSE TO TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: PROBABILITY PLOT ANALYSIS OF RESULTS FROM A 48-WEEK PHASE 3B/4 METHOTREXATE WITHDRAWAL STUDY
    Cohen, S. B.
    Chen, Y. H.
    Sugiyama, N.
    Rivas, J. L.
    Diehl, A.
    Lukic, T.
    Paulissen, J.
    Fan, H.
    Hirose, T.
    Keystone, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 564 - 565
  • [27] CLINICAL OUTCOMES OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥65 YEARS: A POST HOC SUBGROUP ANALYSIS OF PHASE 2 AND 3 CLINICAL TRIALS AND ONGOING LONG-TERM EXTENSIONS
    Buch, Maya H.
    Combe, Bernard
    Gomez-Puerta, Jose A.
    Caporali, Roberto
    Gottenberg, Jacques-Eric
    Van Hoek, Paul
    Rajendran, Vijay
    Stiers, Pieter-Jan
    Van Beneden, Katrien
    Aletaha, Daniel
    Burmester, Gerd
    Westhovens, Rene
    Tanaka, Yoshiya
    RHEUMATOLOGY, 2023, 62
  • [28] RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3B/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS
    Charles-Schoeman, C.
    Fleischmann, R. M.
    Mysler, E.
    Greenwald, M.
    Wang, C.
    Chen, A. S.
    Connell, C. A.
    Woolcott, J.
    Menon, S.
    Chen, Y.
    Lee, K.
    Szekanecz, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 358 - 359
  • [29] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor: Analysis of Infections and All-Cause Mortality Across Phase 3 and Long-Term Extension Studies in Patients with Rheumatoid Arthritis.
    Cohen, S.
    Radominski, S. C.
    Asavatanabodee, P.
    Wood, S. P.
    Soma, K.
    Nduaka, C. I.
    Wang, L.
    Gruben, D.
    Valdez, H.
    Zwillich, S. H.
    Bradley, J.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S153 - S153
  • [30] STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY
    Ritchlin, C. T.
    Mease, P. J.
    Boehncke, W. H.
    Tesser, J.
    Chakravarty, S. D.
    Rampakakis, E.
    Shawi, M.
    Schiopu, E.
    Merola, J. F.
    Mcinnes, I.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1779 - 1780
1234